Current Medical Research and Opinion最新文献

{"title":"Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine.","authors":"Pratap Chokka, Lene Hammer-Helmich, Simon Nitschky Schmidt, Martine Hubert, Elin H Reines, Iria Grande","doi":"10.1080/03007995.2025.2503976","DOIUrl":"https://doi.org/10.1080/03007995.2025.2503976","url":null,"abstract":"<p><p>This narrative review used manufacturer-sponsored vortioxetine clinical trial database (doses of 5-20 mg) to evaluate the effect of vortioxetine treatment on short- and long- term functional outcomes in major depressive disorder (MDD), in both the clinical trial setting and in routine practice. The Sheehan Disability Scale (SDS) was the most used functional scale and, based on this measure, short-term, placebo-controlled studies demonstrated significant improvements with vortioxetine 10 mg (reductions ranged from -0.92 to -2.10 points vs placebo after 6-8 weeks treatment) and 20 mg (reductions ranged from -0.88 to -3.92 vs placebo). Of note, the acute beneficial effects of vortioxetine on functionality were seen in patients with severe baseline depressive symptoms as well as those with significant anxiety. Long-term open-label extension studies further showed that maintenance treatment was associated with continued functional improvements over one year (reaching an average reduction of -6.2 SDS points from baseline) that were correlated with continued improvements in residual symptoms. Evidence from real-world studies, using multiple functional outcomes, further demonstrated generalizability to routine practice where patients are living with multiple comorbidities previously excluded from the randomized controlled trials. Taken overall, the findings from several head-to-head studies indicated a functional advantage of vortioxetine compared with other classes of antidepressants and demonstrated the effectiveness of vortioxetine as first-line treatment while also confirming its effectiveness in improving functional outcomes when given later in the treatment journey. In summary, vortioxetine is an effective treatment option for improving functional outcomes in people living with MDD.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-12"},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"GPP 2022: perspectives, sentiments, and feedback from the publications community.","authors":"Raghuraj Puthige, Dikran Toroser, Anisha Mehra, Dhanya Mukundan, Anupama Kapadia","doi":"10.1080/03007995.2025.2503975","DOIUrl":"10.1080/03007995.2025.2503975","url":null,"abstract":"<p><strong>Objective: </strong>To identify the impact and integration of GPP 2022 guidelines on the work processes of publications developed in pharmaceutical, publishing, agency, and academic circles.</p><p><strong>Methods: </strong>A cross-sectional survey was conducted for 3 weeks from March 1-22, 2024 among medical publication professionals and healthcare researchers. The survey included questions that have been traditionally challenging in publication workstreams and were disseminated through major medical communications networking groups. The survey results were summarized as a percentage for each answer rounded to one decimal place.</p><p><strong>Results: </strong>A total of 100 participants responded to the survey among whom 67.0% were familiar with the GPP 2022 guidelines. To mitigate potential misinterpretation risks, we considered only respondents familiar with the guidelines. More than half of the respondents (55.7%) felt that GPP 2022 was effective in addressing ethical considerations; 34.4% respondents agreed that GPP 2022 provided useful guidance on best practices in transparency and data-sharing. Most survey respondents (54.5%) agreed that the authorship and contributorship criteria were clear in GPP 2022. 37.3% of the survey respondents were familiar with publication extenders and felt that extenders added value to the dissemination of research findings; 39.2% were aware of plain-language summaries and 82.4% viewed them as vital for widespread research accessibility.</p><p><strong>Conclusion: </strong>The survey suggests a need to improve awareness and support for implementing transparency initiatives that aid in the publication process. Furthermore, although most respondents were aware of publication extenders, there was a need for clarification and harmonization of guidelines on publication extenders.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-7"},"PeriodicalIF":2.4,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A letter to the editor in response to: indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.","authors":"Hannah R Volkman, Santiago M C Lopez, Mary M Moran, Haitao Chu, Joseph C Cappelleri, Jennifer L Nguyen, John M McLaughlin, Alejandro D Cane","doi":"10.1080/03007995.2025.2502123","DOIUrl":"https://doi.org/10.1080/03007995.2025.2502123","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-3"},"PeriodicalIF":2.4,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tobacco smoking and sarcoidosis revisited-Evidence, mechanisms, and clinical implications: a narrative review.","authors":"Nadia Sweis, Arnaud Dominati, Supritha Prasad, Fatima Alnaimat, Mina Alawqati, Israel Rubinstein, Rachel Caskey","doi":"10.1080/03007995.2025.2495852","DOIUrl":"https://doi.org/10.1080/03007995.2025.2495852","url":null,"abstract":"<p><p>Sarcoidosis is a multisystem inflammatory disease with unclear etiology, influenced by genetic predisposition and environmental exposures. Smoking has been widely studied for its potential role in sarcoidosis, with conflicting evidence regarding its impact on disease risk, severity, and treatment response. While some epidemiologic studies suggest that smoking is associated with a lower risk of sarcoidosis, others highlight variations based on geography, ethnicity, and smoking history. Assessing the effects of smoking is particularly challenging because of the complex composition of tobacco smoke, which contains thousands of chemicals with diverse biologic effects. Nicotine, a major component of tobacco, has demonstrated both pro- and anti-inflammatory properties, further complicating its role in sarcoidosis. This narrative review explored the complex relationship between smoking and sarcoidosis by examining smoking's effects on immune modulation, disease presentation and prognosis, and response to immunosuppressive therapy. By summarizing current evidence, this paper aimed to clarify the impact of smoking and nicotine on sarcoidosis and identify key areas for future research, particularly in understanding the mechanisms underlying smoking-related immune modulation and treatment outcomes.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"1-16"},"PeriodicalIF":2.4,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood pressure management in the first 24 hours for intracerebral hemorrhage patients on oral anticoagulant therapy.","authors":"Lindsey Selph, Teresa A Allison, Sophie Samuel","doi":"10.1080/03007995.2025.2495853","DOIUrl":"10.1080/03007995.2025.2495853","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the differences in blood pressure (BP) management and outcomes between intracerebral hemorrhage (ICH) patients on oral anticoagulant (OAC) therapy compared to those not on OAC therapy within the first 24 h of hospital admission.</p><p><strong>Methods: </strong>This retrospective cohort study included 165 ICH patients admitted to a comprehensive stroke center between July 1, 2014 and June 30, 2021. Patients were divided into two groups: those on OAC therapy (<i>n</i> = 55) and those not on OAC therapy (<i>n</i> = 110). BP measurements, including systolic BP (SBP) within 24 h of post-admission, were recorded. Clinical outcomes, such as mortality, modified Rankin Scale (mRS) scores, and length of hospital stay, were assessed. Kaplan-Meier survival analysis and Cox proportional hazards regression were used to evaluate the impact of BP management on patient outcomes.</p><p><strong>Results: </strong>No significant differences in overall survival were observed between the OAC and non-OAC groups. Although the mean SBP at 24 h was slightly higher in the OAC group (142 mmHg) compared to the non-OAC group (136 mmHg; <i>p</i> = 0.032), this did not translate into differences in mortality or functional outcomes. Higher ICH scores were associated with increased mortality risk (HR 2.01, 95% CI 1.29-3.12, <i>p</i> = 0.002). Higher GCS scores were associated with better functional outcomes (HR 0.92, 95% CI 0.85-0.99, <i>p</i> = 0.035), while BP management strategies did not show a significant impact.</p><p><strong>Conclusion: </strong>BP management in the first 24 h for ICH patients on OAC may not significantly affect mortality or functional outcomes. Current BP management strategies may be applicable to both OAC and non-OAC patients, though further research is needed to explore tailored approaches.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"733-740"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143986817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sodium-glucose cotransporter 2 inhibitors in transthyretin amyloid cardiomyopathy: navigating potential benefits and uncertainties.","authors":"Paschalis Karakasis","doi":"10.1080/03007995.2025.2495167","DOIUrl":"10.1080/03007995.2025.2495167","url":null,"abstract":"<p><p>Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have garnered attention for their potential role in managing transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive condition characterized by significant morbidity and mortality. ATTR-CM remains underdiagnosed despite advances in diagnostic modalities. While tafamidis and acoramidis have emerged as effective therapies, residual cardiovascular risk persists, highlighting the need for adjunctive treatments. SGLT2i, initially developed as antidiabetic agents, have demonstrated cardioprotective effects in various heart failure phenotypes, including preserved and reduced ejection fractions. Emerging evidence suggests their utility in ATTR-CM, potentially addressing unmet needs, such as symptom burden, hospitalizations, and survival. Clinical studies indicate that SGLT2i reduce all-cause mortality, major adverse cardiac events (MACE), and heart failure hospitalizations, with benefits extending to cardiovascular mortality and improved functional status. Moreover, these agents appear to mitigate arrhythmic complications, evidenced by reduced cardioversion procedures and antiarrhythmic therapy requirements. Observational studies also highlight the potential synergy of SGLT2i with tafamidis, suggesting additive benefits in addressing amyloid deposition and heart failure. However, limitations, including the absence of randomized controlled trials, immortal time bias, and population heterogeneity, necessitate further research. Future directions involve elucidating mechanisms of action, exploring personalized treatment strategies, and leveraging big data analytics for real-world insights. SGLT2i's potential to transform ATTR-CM management underscores their promise, though robust trials are imperative to validate findings and optimize clinical applications.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"657-661"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect comparison of the relative vaccine effectiveness of mRNA-1283 vs. BNT162b2 vaccines against symptomatic COVID-19 among US adults.","authors":"Ekkehard Beck, Mihaela Georgieva, Wei-Jhih Wang, Andres Gomez-Lievano, Hongjue Wang, Yipeng Gao, Hagit Kopel, Mary Bausch-Jurken, Oscar Patterson-Lomba, Fan Mu, Eric Wu, Nicolas Van de Velde","doi":"10.1080/03007995.2025.2466726","DOIUrl":"10.1080/03007995.2025.2466726","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 continues to pose a significant health burden, particularly among older adults. mRNA-1283 is a next-generation COVID-19 mRNA vaccine developed to enhance immune response. Findings from the Phase 3 NextCOVE trial comparing bivalent versions of mRNA-1273 and mRNA-1283 vaccines have recently become available. However, there are no head-to-head trials comparing mRNA-1283 and the BNT162b2 vaccine.</p><p><strong>Objective: </strong>To indirectly compare the effectiveness of mRNA-1283 and BNT162b2 against symptomatic COVID-19 among adults in the US.</p><p><strong>Methods: </strong>A targeted literature review was conducted to identify relevant studies comparing the mRNA-1273 and BNT162b2 bivalent vaccines. A real-world evidence (RWE) study by Kopel et al. (2023) assessing the relative vaccine effectiveness (rVE) of mRNA-1273 vs. BNT162b2 was selected for an indirect treatment comparison (ITC) against the NextCOVE trial using the Bucher method. Analyses were stratified by age group and sensitivity analyses were conducted using alternative outcome definitions.</p><p><strong>Results: </strong>Despite differences between NextCOVE and the Kopel study, comparability assessments supported a robust ITC. Among participants ≥18 years of age, the indirect rVE of mRNA-1283 vs. BNT162b2 against symptomatic COVID-19 was 15.3% (95% CI = 4.7-24.8%, <i>p</i> = 0.006). For adults ≥65 years of age, the rVE was 22.8% (95% CI = 3.7-38.1%, <i>p</i> = 0.022). Sensitivity analyses with alternative outcome definitions supported these estimates.</p><p><strong>Conclusion: </strong>This analysis provides consistent and statistically significant evidence indicating the next-generation mRNA-1283 vaccine is more effective in preventing symptomatic COVID-19 than BNT162b2, with the largest effect in individuals aged ≥65. Consistent results across sensitivity analyses underscore the robustness of the findings, offering important evidence to inform vaccination decisions by policymakers, providers, and payers.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"721-732"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frontiers in bibliometric analysis: the overrepresentation of bibliometric analyses in Grey publisher journals.","authors":"Joshua Wang","doi":"10.1080/03007995.2025.2488949","DOIUrl":"10.1080/03007995.2025.2488949","url":null,"abstract":"","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"667-668"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143771730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of OFF period characteristics with patient communication behaviors in Parkinson's disease.","authors":"Radhika Devraj, Connie Marras, Marlon R Tracey","doi":"10.1080/03007995.2025.2495171","DOIUrl":"10.1080/03007995.2025.2495171","url":null,"abstract":"<p><strong>Objective: </strong>Underreporting of OFF symptoms and poor patient-provider communication are known challenges in Parkinson's disease (PD). We aimed to determine: (a) OFF period patient communication behavior components and (b) whether OFF period characteristics (frequency, duration, severity) were associated with communication behaviors.</p><p><strong>Methods: </strong>A retrospective cohort study using the Fox Insight database was conducted. OFF periods were characterized by frequency (number of episodes/day), duration (duration/episode), and severity (impact on activities). The \"Impact and Communication about OFF periods\" questionnaire data were subjected to principal components analysis. Generalized linear model regressions with log link function were used to identify associations with OFF period characteristics.</p><p><strong>Results: </strong>Data from 526 respondents showed that 89% were non-Hispanic whites, mean age = 65 ± 8.9 years, with PD duration = 6 ± 4.8 years. The majority (67%) had a frequency of 1-2 OFF periods/day, with the highest percent (31.4%) having 15-30 min OFF periods duration, and majority (63%) having none-to-some OFF periods severity. Two component communication behaviors were identified: (1) reluctance communicating (7 items, Cronbach's alpha (CA) = 0.851) and difficulty communicating (4 items, CA = 0.857). Above-average OFF periods severity was associated with a 12% higher reluctance score (beta = 0.117, 95% confidence interval (CI) = 0.03-0.21, <i>p</i> = 0.024). Higher OFF periods frequency and above-average severity were associated with greater difficulty communicating (Frequency: beta = 0.125, 95% CI = 0.03-0.22, <i>p</i> = 0.024; Severity: (beta = 0.186, 95% CI = 0.08-0.29, <i>p</i> = 0.003)) about OFF periods.</p><p><strong>Conclusion: </strong>Patient communication about OFF periods involves two main factors: their difficulty and reluctance to communicate. Greater frequency and severity of OFF periods were associated with greater difficulty and reluctance to communicate. Understanding these relationships can guide providers to take preemptive efforts to promote OFF periods communication, enhancing care quality.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"647-656"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incremental healthcare costs among patients experiencing adverse events on oral antipsychotics: a real-world analysis of U.S. Medicare beneficiaries with schizophrenia.","authors":"Christopher Zacker, Justin T Puckett, Sachin Kamal-Bahl","doi":"10.1080/03007995.2025.2493344","DOIUrl":"10.1080/03007995.2025.2493344","url":null,"abstract":"<p><strong>Objective: </strong>Continuous antipsychotic treatment is fundamental to successful management of schizophrenia. However, many oral antipsychotics are associated with adverse effects (AEs). While prior research has shown antipsychotic AEs to negatively impact patient adherence, no study has examined the incremental costs associated with AEs, especially among Medicare beneficiaries who constitute approximately half of all patients with schizophrenia in the U.S. This study aimed to compare incremental healthcare costs among Medicare beneficiaries with schizophrenia treated with oral antipsychotics who did and did not experience adverse events (AEs).</p><p><strong>Methods: </strong>All fee-for-service Medicare beneficiaries with schizophrenia who initiated a new OAP between 01/01/2017 and 12/31/2019 were included in the sample (index date = date of new OAP prescription). All-cause and schizophrenia-related costs were measured while a patient was receiving treatment and were converted into monthly measures given differential follow-up periods. Generalized linear models were used to generate adjusted cost estimates.</p><p><strong>Results: </strong>In our final sample of 46,452 Medicare beneficiaries with schizophrenia, movement disorders such as tardive dyskinesia and extrapyramidal symptoms were observed in 10.0% of beneficiaries. Metabolic side effects included hyperlipidemia (33.6%), diabetes (33.1%), and hypotension (6.8%). Patients who experienced adverse events consistently had significantly higher all-cause monthly healthcare costs compared to patients who did not experience adverse events. This was true for beneficiaries experiencing movement disorders ($5,281 vs. $4,851, Δ = $430, <i>p</i> = 0.0766), hyperlipidemia ($5,123 vs. $4,768, Δ = $355, <i>p</i> = 0.0179), diabetes ($5,249 vs. $4,698, Δ = $551, <i>p</i> = 0.0049), and hypotension ($6,631 vs. $4,685, Δ = $1,946, <i>p</i> < 0.001). A similar pattern was observed for monthly schizophrenia-related costs.</p><p><strong>Conclusions: </strong>Our findings underscore the additional healthcare cost burden associated with adverse events in patients receiving oral antipsychotic treatment. Efforts should be directed towards selecting agents that minimize side effects and/or developing new therapeutic alternatives with improved tolerability profiles.</p>","PeriodicalId":10814,"journal":{"name":"Current Medical Research and Opinion","volume":" ","pages":"587-592"},"PeriodicalIF":2.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}